RadNet acquires Truxtun Medical Group

RadNet, Inc. (Nasdaq:RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 185 fully-owned and operated outpatient imaging centers, today reported it has completed the previously announced acquisition of Truxtun Medical Group.

Subsequent to the end of the fourth quarter, the Company entered into a letter of intent to acquire the business of Truxtun Medical Group in Bakersfield, California. Truxtun operates four multi-modality facilities in Bakersfield, a Metropolitan Statistical Area with a population exceeding 800,000 residents in Kern County, California. Truxtun provides a broad range of services including MRI, CT, PET/CT, mammography, nuclear medicine, fluoroscopy, ultrasound, x-ray and related procedures.

 "We are very excited to welcome the many outstanding employees of Truxtun into the RadNet organization. Through its four multi-modality facilities, Truxtun has an exemplary reputation for providing high-quality service to the patients and referring community of the greater Bakersfield area. We believe that Truxtun will be a platform from which we can further grow in Bakersfield and surrounding areas in the Central Valley of California," said Dr. Howard Berger, President and Chief Executive Officer of RadNet.

Dr. Berger added, "Our recently completed financing transaction has positioned us with the financial flexibility and capability to capitalize on other similar opportunities in this and other markets. While we continue to pursue multi-modality assets in the markets in which we currently operate, we remain disciplined with respect to paying purchase multiples that are at or below RadNet's current leverage ratio."

As previously announced in March 2010, the Company entered into a letter of intent to acquire the New Jersey operating subsidiary of Health Diagnostics. The Company expects to complete this transaction within the next thirty days.

Source:

RadNet, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-powered lesion delineation in prostate cancer PET/CT imaging